Drugs / DA414
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06525168 | Feb 2024 → Sep 2025 overdue | ischemic stroke | Chendu DIAO Nine Hong Pharmaceutical Factory | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA414 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06525168 ↗ |
| Known as | DA414 Granules | “DA414 Granules single ascending doses.” NCT06525168 ↗ |
| Route | Oral | “DA414 will be orally administrated” NCT06525168 ↗ |